MIDWEST BIOPROCESSING CENTER LLC
Peoria, IL · Biotech · Private
Engineered E. coli system to biosynthesize rare 6-deoxysugars and amino sugars for use in glycoengineering and natural product modification
mwbioprocessing.com →- Grants
- $7.1M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Engineering Methylotrophic Yeast for in vivo Production of Deoxysugars from DHAP | $193,138 | |
| Federal grant | Department of Health and Human Services · Phase II · Activated Sugars, Oligosaccharides and Glycans for Antiviral Research | $982,971 | |
| Federal grant | Department of Health and Human Services · Phase II · Activated Sugars, Oligosaccharides and Glycans for Antiviral Research | $1,851,010 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Production of Natural Deoxysugars for Chemical Synthesis of Glycosides | $217,421 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Production of Natural Deoxysugars for Chemical Synthesis of Glycosides | $217,421 | |
| Federal grant | Department of Health and Human Services · Phase II · Activated Sugars, Oligosaccharides and Glycans for Antiviral Research | $868,039 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Production of Natural Deoxysugars for Use in Chemical Synthesis of Glycosides | $930,179 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Production of Natural Deoxysugars for Use in Chemical Synthesis of Glycosides | $930,179 | |
| Federal grant | Department of Health and Human Services · Phase II · Production of Natural Deoxysugars for Use in Chemical Synthesis of Glycosides | $867,968 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2719 | GLYTR THERAPEUTICS, INC. | — | — |
| 2720 | SCINTILLATION NANOTECHNOLOGIES INC | — | — |
| 2721 | COMPUTCHEM LLC | — | — |
| 2722 | MIDWEST BIOPROCESSING CENTER LLC | — | — |
| 2723 | Accuronix Therapeutics Inc | — | — |
| 2724 | Alveus Pharma | — | — |
| 2725 | SEVEN BIOSCIENCES, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Formulations and Applications of Feruloyl Glyceridesapplication
- Formulations And Applications Of Feruloyl Glyceridesapplication
- Formulations and Applications of Feruloyl Glyceridesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.